Nostrum Pharmaceuticals Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties
11/29/2010 6:44:21 AM
More...
|
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
2/24/2009 9:43:15 AM
More...
|
Nostrum Pharmaceuticals Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
4/22/2008 8:28:12 AM
More...
|
Synovics Pharmaceuticals, Inc. (SYVC.OB) Announces the Settlement of all Legal Proceedings with Nostrum Pharmaceuticals., Dr. Nirmal Mulye and Anil Anand
8/7/2007 1:37:05 PM
More...
|
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From Institute of Microbial Technology (IMTECH) For Clinical Development Of A Novel Clot Busting Therapeutic Protein
7/28/2006 10:17:28 AM
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: CARBATROL(R) Paragraph IV Litigation Update
10/19/2005 5:11:39 PM
More...
|
Elite Pharmaceuticals, Inc. (ELI) Announces End Of Negotiations With Nostrum Pharmaceuticals
10/19/2005 5:11:09 PM
More...
|
Nostrum Pharmaceuticals Confident Regarding Outcome Of Shire Laboratories' Carbamazepine ER Litigation
10/19/2005 5:09:02 PM
More...
|